5 Pharmaceutical Stocks to Buy According to Jim Simons’ Euclidean Capital

Page 5 of 5

1. PMV Pharmaceuticals, Inc. (NASDAQ:PMVP

Euclidean Capital’s Stake Value: $133 million

Percentage of Euclidean Capital’s 13F Portfolio: 31.2%

Number of Hedge Fund Holders: 18

The share price of PMV Pharmaceuticals, Inc. (NASDAQ:PMVP), the largest stock holding of billionaire Jim Simons’ Euclidean Capital, has been struggling to rebound so far this year. Meanwhile, some firms are seeing the dip as a buying opportunity. Goldman Sachs lifted its price target for PMV Pharmaceuticals to $43 with a Buy rating, citing strong data for its p53 reactivator PC14586, which is in Phase 1 trial for solid tumors. 

You can also take a look at Goldman Sachs Stock Portfolio: Top 10 Stocks and 10 Pharmaceutical Stocks to Buy According to Lawrence Hawkins’ Prosight Capital.

Page 5 of 5